TriangleBiopsy Procedure (NCT06126276)
Biopsy Procedure trial for Malignant Female Reproductive System Neoplasm (NCT06126276). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or persistent HER2-positive solid tumors other than breast cancer, meeting ComboMATCH testing criteria, without known RB1 loss. Prior HER2-targeted kinase inhibitors or CDK4/6 inhibitors are excluded.
The idea: compare oral neratinib alone with neratinib plus palbociclib. Neratinib blocks HER2 growth signals; palbociclib blocks proteins that control cell division. Researchers measure time before progression. Both groups start with neratinib alone.
This phase 2 study plans 70 patients. Haider Mahdi leads through NRG Oncology; 180 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.